Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Health Canada approves letrozole
May 5th, 2005
Health Canada has approved Femara (letrozole; Novartis Pharmaceuticals Canada, Inc.) for the extended adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy. The approval is based on the results of a clinical trial, known as MA-17, in which Femara was shown to significantly reduce both the recurrence of breast cancer and distant metastases (spread of the disease) to the rest of the body after standard adjuvant treatment with 5 years of tamoxifen. Femara, an aromatase inhibitor, is an oral once-a-day drug indicated as first-line...
Source: Women's Health Weekly (2005-05-05)
|
